Confluent Medical Technologies Archives

Confluent invests to expand ATI nitinol melting infrastructure

NEWS RELEASE: Confluent Announces Significant Investment in ATI Nitinol Melt Expansion

Confluent Becomes ATI’s Fulfillment Partner for Medical Nitinol

Scottsdale, AZ- Confluent Medical Technologies (Confluent) announced that it has partnered with ATI to invest more than $50 million over the next several years in ATI’s Nitinol melt and materials conversion infrastructure. With this significant investment, which will more than triple ATI’s melt capacity for medical Nitinol, Confluent will become ATI’s fulfillment partner and provide a suite of value-add services and order-fulfillment for ATI medical Nitinol mill product.

Confluent CEO and President Dean Schauer [Photo courtesy of Confluent]

“The growth in Neurovascular, Electrophysiology, Structural Heart, Peripheral Vascular, and Orthopedic device markets is driving an 18% growth rate (CAGR) in Nitinol demand. Given the substantial equipment and infrastru…

Confluent Medical now offers EU MDR-compliant polyimide tubing

[Image courtesy of Confluent Medical]

Confluent Medical Technologies announced today that it now offers REACH and EU MDR-compliant polyimide tubing.

REACH, a European Union regulation, imposes stringent limitations for the EU market. It covers the amount of restricted substances contained in devices sold in the EU. It stands for Registration, Evaluation, Authorization, and Restriction of Chemicals. The industry-standard polyimide contains one of the restricted solvents. Common uses for polyimide include medical applications such as vascular catheters.

Confluent Medical said its REACH-compliant material uses industry-standard chemistry. It results in a product that looks and performs like traditional polyimide. However, it avoid the historical hurdles that need clearing to ensure EU compliance.

The company said it plans to offer the REACH-compliant polyimide immediately with lead times of four week…

Confluent Medical Technologies appoints new CFO

Confluent Medical Technologies announced today that it appointed Matthew Eckl as its new chief financial officer (CFO).

The Scottsdale, Arizona-based company made Eckl’s appointment effective today. His responsibilities include global financial strategy and financial operations. The company intends for Eckl to lead its accounting, financial planning and analysis, legal and information technology teams.

“We are thrilled to welcome Matt to Confluent,” said Dean Schauer, Confluent CEO. “Matt has exceptional experience in finance and financial operations as well as leadership across a variety of design and manufacturing organizations. As Confluent continues its significant growth, the addition of Matt to our company will further enhance the strength of our industry-leading team.”

Eckl previously served as CFO for five years at Dallas, Texas-based CECO Environmental. Before that, his experience included VP of finance for the ener…

Confluent Medical expands Costa Rica manufacturing footprint for nitinol, complex catheter production

Confluent Medical Technologies this week announced the opening of its new addition to its Costa Rica manufacturing facility.

The expansion adds 66,000 sq. ft to its large-scale manufacturing center of excellence in Alajuela, Costa Rica to expand Confluent’s capacity for nitinol component processing and complex catheter manufacturing.

“Confluent has experienced consistent and strong growth in recent years,” President and CEO Dean Schauer said. “This expansion supports our new product pipeline which continues to grow at a rate greater than Confluent has previously experienced.”

Confluent Medical produces components for numerous medical device markets, including interventional neuromuscular, electrophysiology, structural heart and peripheral vascular. Because of the double-digit growth the company has experienced, the new expansion in Costa Rica will begin making new products that are coming into production.

The company …

Confluent Medical Technologies closes majority investment from TPG Capital

Confluent Medical Technologies announced that it closed a majority investment from TPG Capital following TPG’s agreement to acquire a majority stake in the company.

Last month, Confluent Medical confirmed that TPG Capital signed a definitive agreement to acquire a majority stake in the company, joining existing investor Ampersand Capital Partners, which retains a substantial minority interest, according to a news release.

Confluent develops and manufactures Nitinol-based medical components and specializes in prototyping designing, developing and manufacturing implants, delivery systems and other components for neurovascular, electrophysiology, structural heart, peripheral vascular and minimally invasive procedures.

The company touted the closing of the investment as the latest step forward in a period of momentum, having developed film cast capabilities for PTFE liners and polyimide tubing, invested into electrospinning capabilities and expanded in…

TPG Capital makes majority investment in Confluent Medical Technologies

Confluent Medical Technologies announced today that TPG Capital agreed to make a majority investment in the company.

TPG Capital joins Amerpand Capital Partners, an existing investor that will retain a substantial minority interest in Confluent, according to a news release.

Scottsdale, Arizona-based Confluent partners OEMs to support the design, development and manufacturing of life-saving implants, minimally invasive delivery systems and other medical devices.

“Confluent’s depth of expertise in Nitinol processing and other complex modalities, differentiated manufacturing capabilities and unique end-to-end integration have positioned the company as a trusted design and manufacturing partner to OEMs for many of the most complex implantable products,” TPG Capital Partner Kendall Garrison said in the release.

J.P. Morgan Securities LLC acted as the exclusive financial advisor and Goodwin Procter LLP served as the legal counsel to Confluent in this tr…